Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890714902> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2890714902 endingPage "e23148" @default.
- W2890714902 startingPage "e23148" @default.
- W2890714902 abstract "e23148 Background: Over half of papillary thyroid cancers (PTC) contain the MAPK pathway activating, oncogenic BRAF V600E mutation. Early clinical trials using inhibitors to this mutant protein or its substrates, the MEK1/2 kinases, prolonged progression-free survival or stabilized disease in patients with advanced PTC. However, the toxicities of these inhibitors are uniquely highlighted in an indolent disease like PTC, which would require patients to endure toxicities long-term. Our goal was to determine if tetrathimoybdate (TM), a well-tolerated copper chelator we have previously shown to inhibit BRAF-mutated melanoma via MEK inhibition, can inhibit BRAF-driven PTC growth. Methods: We assessed TM in comparison to current standard of care (SOC), Lenvatinib and Sorafenib, and mutant BRAF inhibitor, Vemurafenib. Anchorage independent growth assays were used to test the inhibitory effect of these drugs on human BRAF-mutated PTC cell lines. We then confirmed these findings by treating a genetically engineered mouse model (GEMM) of aggressive BRAF-driven PTC. Results: TM inhibited 57.5% of colony growth in vitro, which was not significantly different from the 42.4% and 32.2% inhibition by Sorafenib and Lenvatinib, respectively. TM inhibition was less effective than the 70.3% inhibition by Vemurafenib ( p =0.04). We confirmed these results in vivo, where mice on the TM arm, on average, were observed to have 14.8% of their thyroid glands occupied by tumor, a statistically significant reduction from the mice in the control arm, whose tumor load averaged 23.6% ( p= 0.008). This 37.4% reduction in tumor burden was not statistically different from the 35.2% reduction measured in the Vemurafenib arm, where mice on average had 15.3% of their thyroid glands replaced by tumor. Conclusions: The copper chelator, TM, was as effective as the SOCs, Lenvatinib and Sorafenib, at inhibiting the growth of human PTC in vitro. Although TM was slightly less effective than Vemurafenib in vitro, TM was as effective as Vemurafenib at reducing tumor load in a GEMM of BRAF-driven PTC. Success of TTM in these PTC models may next inform a Phase I trial assessing TM in patients with advanced PTC." @default.
- W2890714902 created "2018-09-27" @default.
- W2890714902 creator A5039439529 @default.
- W2890714902 creator A5063852242 @default.
- W2890714902 creator A5069910935 @default.
- W2890714902 creator A5072576684 @default.
- W2890714902 date "2017-05-20" @default.
- W2890714902 modified "2023-09-23" @default.
- W2890714902 title "Copper chelation as targeted therapy in a genetic mouse model of oncogenic BRAF-driven thyroid cancer." @default.
- W2890714902 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e23148" @default.
- W2890714902 hasPublicationYear "2017" @default.
- W2890714902 type Work @default.
- W2890714902 sameAs 2890714902 @default.
- W2890714902 citedByCount "1" @default.
- W2890714902 countsByYear W28907149022022 @default.
- W2890714902 crossrefType "journal-article" @default.
- W2890714902 hasAuthorship W2890714902A5039439529 @default.
- W2890714902 hasAuthorship W2890714902A5063852242 @default.
- W2890714902 hasAuthorship W2890714902A5069910935 @default.
- W2890714902 hasAuthorship W2890714902A5072576684 @default.
- W2890714902 hasConcept C121608353 @default.
- W2890714902 hasConcept C126322002 @default.
- W2890714902 hasConcept C150903083 @default.
- W2890714902 hasConcept C184235292 @default.
- W2890714902 hasConcept C207001950 @default.
- W2890714902 hasConcept C2776131300 @default.
- W2890714902 hasConcept C2776264508 @default.
- W2890714902 hasConcept C2777658100 @default.
- W2890714902 hasConcept C2778019345 @default.
- W2890714902 hasConcept C2778695046 @default.
- W2890714902 hasConcept C2779707156 @default.
- W2890714902 hasConcept C2779761222 @default.
- W2890714902 hasConcept C2781249067 @default.
- W2890714902 hasConcept C2781461381 @default.
- W2890714902 hasConcept C2994587330 @default.
- W2890714902 hasConcept C502942594 @default.
- W2890714902 hasConcept C54355233 @default.
- W2890714902 hasConcept C57074206 @default.
- W2890714902 hasConcept C62112901 @default.
- W2890714902 hasConcept C71924100 @default.
- W2890714902 hasConcept C86803240 @default.
- W2890714902 hasConcept C95444343 @default.
- W2890714902 hasConceptScore W2890714902C121608353 @default.
- W2890714902 hasConceptScore W2890714902C126322002 @default.
- W2890714902 hasConceptScore W2890714902C150903083 @default.
- W2890714902 hasConceptScore W2890714902C184235292 @default.
- W2890714902 hasConceptScore W2890714902C207001950 @default.
- W2890714902 hasConceptScore W2890714902C2776131300 @default.
- W2890714902 hasConceptScore W2890714902C2776264508 @default.
- W2890714902 hasConceptScore W2890714902C2777658100 @default.
- W2890714902 hasConceptScore W2890714902C2778019345 @default.
- W2890714902 hasConceptScore W2890714902C2778695046 @default.
- W2890714902 hasConceptScore W2890714902C2779707156 @default.
- W2890714902 hasConceptScore W2890714902C2779761222 @default.
- W2890714902 hasConceptScore W2890714902C2781249067 @default.
- W2890714902 hasConceptScore W2890714902C2781461381 @default.
- W2890714902 hasConceptScore W2890714902C2994587330 @default.
- W2890714902 hasConceptScore W2890714902C502942594 @default.
- W2890714902 hasConceptScore W2890714902C54355233 @default.
- W2890714902 hasConceptScore W2890714902C57074206 @default.
- W2890714902 hasConceptScore W2890714902C62112901 @default.
- W2890714902 hasConceptScore W2890714902C71924100 @default.
- W2890714902 hasConceptScore W2890714902C86803240 @default.
- W2890714902 hasConceptScore W2890714902C95444343 @default.
- W2890714902 hasIssue "15_suppl" @default.
- W2890714902 hasLocation W28907149021 @default.
- W2890714902 hasOpenAccess W2890714902 @default.
- W2890714902 hasPrimaryLocation W28907149021 @default.
- W2890714902 hasRelatedWork W1968041503 @default.
- W2890714902 hasRelatedWork W2160405811 @default.
- W2890714902 hasRelatedWork W2164992866 @default.
- W2890714902 hasRelatedWork W2328771497 @default.
- W2890714902 hasRelatedWork W2886296250 @default.
- W2890714902 hasRelatedWork W3034913290 @default.
- W2890714902 hasRelatedWork W3045209127 @default.
- W2890714902 hasRelatedWork W3200436128 @default.
- W2890714902 hasRelatedWork W4313431298 @default.
- W2890714902 hasRelatedWork W4379384795 @default.
- W2890714902 hasVolume "35" @default.
- W2890714902 isParatext "false" @default.
- W2890714902 isRetracted "false" @default.
- W2890714902 magId "2890714902" @default.
- W2890714902 workType "article" @default.